Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategiesFotios Loupakis
Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy
Cancer 118:1523-32. 2012
..Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indicated for the treatment of metastatic colorectal cancer patients, but some scientific issues concerning their efficacy are currently unsolved...
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patientsFotios Loupakis
Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
Curr Cancer Drug Targets 10:37-45. 2010
..This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity...
- Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer
Fotios Loupakis
University of Pisa, Department of Oncology, Transplants and New Technologies in Medicine, Pisa, Italy
Expert Opin Biol Ther 11:519-31. 2011
....
- Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
Fotios Loupakis
Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy
Cancer Chemother Pharmacol 66:559-66. 2010
..We aimed to evaluate the activity and the safety profile of sequential chemotherapy with 5-FU-based doublets with C, Ir and D in the first-line treatment of AGC...
- PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
Fotios Loupakis
Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
J Clin Oncol 27:2622-9. 2009
..This retrospective study investigated the role of PTEN loss, AKT phosphorylation, and KRAS mutations on the activity of cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC)...
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancerFotios Loupakis
U, O, Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita di Pisa, Italy
BMC Cancer 11:247. 2011
..Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab...
- Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
Mario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
BMC Cancer 9:303. 2009
..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
- Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen
Lorenzo Fornaro
U O Oncologia Medica 2 Universitaria, Polo Oncologico Area Vasta Nord Ovest, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
Clin Colorectal Cancer 11:71-6. 2012
..We evaluated the outcome of second-line treatments among 196 patients treated with first-line FOLFOXIRI in three consecutive trials conducted by the Gruppo Oncologico Nord Ovest group...
- Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases
Gianluca Masi
Unità Operativa Oncologia Medica, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
Ann Surg 249:420-5. 2009
..The objective of this study was to evaluate the long-term outcome of resected patients and the impact of FOLFOXIRI on perioperative morbidities, mortality, and chemotherapy induced hepatotoxicity...
- Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
Gianluca Masi
U O Oncologia Medica 2 Universitaria Polo Oncologico, Azienda Ospedaliero Universitaria Pisana, Via Roma, 67 56126 Pisa, Italy
J Natl Cancer Inst 103:21-30. 2011
....
- Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status
Lorenzo Fornaro
U O Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Crit Rev Oncol Hematol 78:243-51. 2011
..Scarce data are available about safety and efficacy of cetuximab in elderly metastatic colorectal cancer (mCRC) patients...
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Gianluca Masi
Unità Operativa Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
Lancet Oncol 11:845-52. 2010
..We therefore assessed the safety and activity of the combination of FOLFOXIRI plus bevacizumab in patients with colorectal cancer...
- Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine
Gianluca Masi
UO Oncologia Medica 2 Universitaria, Ospedale Santa Chiara, Pisa, Italy
Nat Rev Clin Oncol 6:670-4. 2009
..She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective...
- PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
Bruno Vincenzi
Department of Oncology, University Campus Bio Medico, Rome, Italy
J Cell Physiol 227:927-33. 2012
..This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy...
- High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
Daniele Santini
Department of Oncology, University Campus Bio Medico, Rome, Italy
Oncologist 13:1270-5. 2008
..Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases...
- Palliative treatment of unresectable metastatic colorectal cancer
Lorenzo Fornaro
Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Medical Oncology Unit 2, Italy
Expert Opin Pharmacother 11:63-77. 2010
....
- Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Fotios Loupakis
Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Pisa, Italy
Nat Rev Clin Oncol 7:190-1. 2010
....
- Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
Gianluca Masi
Department of Oncology, Azienda USL 6 of Livorno, Istituto Toscano Tumori, Livorno, Italy
Clin Colorectal Cancer 7:7-14. 2008
....
- Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
Fotios Loupakis
UO Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
J Exp Clin Cancer Res 29:58. 2010
..Although the addition of bevacizumab to 1st line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated...
- EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
Fotios Loupakis
Azienda USL 6 Livorno, Division of Medical Oncology, Viale Alfieri 36, 57100 Livorno, Italy
Pharmacogenomics 9:55-69. 2008
..Moving from clinical data suggesting that there could be a subpopulation of CRC patients that are more liable to benefit from anti-EGFR monoclonal antibodies, here we review major studies on determinants of outcome in this field...
- Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer
Gianluca Masi
Department of Oncology, Division of Medical Oncology, Presidio Ospedaliero, Viale Alfieri 36, Livorno, 57124, Italy
Ann Surg Oncol 13:58-65. 2006
..The prognosis of unresectable metastatic colorectal cancer might be improved if a radical surgical resection of metastases could be performed after a response to chemotherapy...
- First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
Fotios Loupakis
Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
Curr Opin Oncol 20:459-65. 2008
..This review focuses on what should be considered to define the optimal approach to each patient, in particular with regard to the intensiveness of first-line chemotherapy...
- Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Fotios Loupakis
Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana and Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
Ther Adv Med Oncol 1:167-81. 2009
....
- The possible role of chemotherapy in antiangiogenic drug resistance
Guido Bocci
Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma 55, Pisa 56126, Italy
Med Hypotheses 78:646-8. 2012
..In conclusion, the consequences of our hypothesis could be promptly translated into the preclinical studies and verified in clinical trials, involving cancer patients resistant to chemotherapy plus antiangiogenic drug schedules...
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
Giacomo Allegrini
Division of Medical Oncology, Pontedera, Pisa, Italy
Angiogenesis 15:275-86. 2012
..To evaluate UFT and cyclophosphamide (CTX) based metronomic chemotherapy plus celecoxib (CXB) for the treatment of patients with heavily pre-treated advanced gastrointestinal malignancies...
